Claim Amendments

Please make the amendments shown below:

1. (Original) A compound selected from the group consisting of:

4-[Amino-(3,5-bis-trifluoromethyl-phenyl)- methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)- methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*S, 4aS*)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)- methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*S, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

(2*R*, 4*S, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*S, 4R, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*S, 4S, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*S, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-

trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*S*, *4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R*, *4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*S*, *4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

(2*R*, 4*R*, *4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

(2*R*, 4*S*, *4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

4-[Amino-(3,5-bis(chloro-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R*, *4aS*)- 4-[Amino-(3,5-bis(chloro-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*S*, *4aS*)- 4-[Amino-(3,5-bis(chloro-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R*, *4aS*)- 4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*S*, *4aS*)- 4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester; and

or a pharmaceutically acceptable salt of said compound.

2. (Original) A compound according to claim 1 selected from the group consisting of:

4-[Amino-(3,5-bis-trifluoromethyl-phenyl)- methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

4-[Amino-(3,5-bis(chloro-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

or a pharmaceutically acceptable salt of said compound.

3. (Original) A compound according to claim 1 selected from the group consisting of:

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)- methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-*2H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

(2*S, 4R, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R, 4aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R, 4aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

(2*R*, 4*R, 4aS*)- 4-[Amino-(3,5-bis(chloro-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R, 4aS*)- 4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

or a pharmaceutically acceptable salt of said compound.

4. (Original) A method for treating atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia,

hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction in a mammal by administering to a mammal in need of such treatment an atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction treating amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound.

5. (Original) A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable vehicle, diluent or carrier.

6. (Original) A pharmaceutical composition for the treatment of atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction in a mammal which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable vehicle, diluent or carrier.

7. (Original) A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1 or a pharmaceutically acceptable salt of said compound;

a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a PPAR modulator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant; and

a pharmaceutical vehicle, diluent or carrier.

8. (Original) A pharmaceutical combination composition as recited in claim 7 wherein the second compound is an HMG-CoA reductase inhibitor or a PPAR modulator.

9. (Original) A pharmaceutical combination composition as recited in claim 8 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin.

10. (Original) A method for treating atherosclerosis in a mammal comprising administering to a mammal in need of treatment thereof;

a first compound, said first compound being a compound of claim 1 or a pharmaceutically acceptable salt of said compound; and

a second compound, said second compound being an HMG CoA reductase inhibitor, a PPAR modulator, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant

wherein the amounts of first and second compounds result in a therapeutic effect.

11. (Original) A method for treating atherosclerosis as recited in claim 10 wherein the second compound is an HMG-CoA reductase inhibitor or a PPAR modulator.

12. (Original) A method for treating atherosclerosis as recited in claim 11 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin.

13. (Original) A kit for achieving a therapeutic effect in a mammal comprising packaged in association a first therapeutic agent comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier, a second therapeutic agent comprising a therapeutically effective amount of an HMG CoA reductase inhibitor, a PPAR modulator, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier and directions for administration of said first and second agents to achieve the therapeutic effect.

14. (Original) A kit as recited in claim 13 wherein said second therapeutic agent comprises an HMG-CoA reductase inhibitor or a PPAR modulator.

15. (Original) A kit as recited in claim 14 wherein said second therapeutic agent comprises lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin.

16. (New) A compound (2R,4R,4aS)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester or a pharmaceutically acceptable salt of said compound.

17. (New) A method for treating atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction in a mammal by administering to a mammal in need of such treatment an atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction treating amount of a compound of claim 16 or a pharmaceutically acceptable salt

of said compound.

18. (New) A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 16 or a pharmaceutically acceptable salt of said compound;

a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a PPAR modulator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant; and

a pharmaceutical vehicle, diluent or carrier.

19. (New) A pharmaceutical combination composition as recited in claim 18 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin or a pharmaceutically acceptable salt thereof.

20. (New) A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

(2R,4R,4aS)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester or a pharmaceutically acceptable salt of said compound;

atorvastatin, or a pharmaceutically acceptable salt of said compound; and

a pharmaceutical vehicle, diluent or carrier.